Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Cutaneous Squamous Cell Carcinoma × Sirolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 38 Leukemia, Myeloid, Acute 32 Myelodysplastic Syndromes 30 Multiple Myeloma 28 Lymphoma, Non-Hodgkin 27 Hodgkin Disease 27 Leukemia, Lymphocytic, Chronic, B-Cell 24 Graft vs Host Disease 24 Lymphoma 23 Leukemia 23 Hematologic Neoplasms 20 Lymphoma, Mantle-Cell 17 Sarcoma 16 Neoplasms 16 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16 Tuberous Sclerosis 14 Myeloproliferative Disorders 14 Lymphoma, Large B-Cell, Diffuse 14 Burkitt Lymphoma 14 Breast Neoplasms 14 Recurrence 12 Lymphoma, Follicular 12 Waldenstrom Macroglobulinemia 11 Primary Myelofibrosis 11 Neoplasm Metastasis 11 Lymphoma, B-Cell, Marginal Zone 11 Leukemia, Myelomonocytic, Chronic 11 Neoplasms, Plasma Cell 10 Melanoma 10 Lymphangioleiomyomatosis 10

Interventions

cemiplimab 3 Transdermal Patch 1 Sirolimus 1 Prednisone 1 Everolimus 1 Doxorubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04339062 2025-04-23

CONTRAC

Dana-Farber Cancer Institute

Phase 1/2 Completed

12 enrolled 13 charts

Cutaneous Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡